Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,196 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 918 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Abdominal Injury, Thoracic Diseases
Interventions: Signia™ Stapling System; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Albany, New York • Cary, North Carolina + 3 more

Conditions: Chronic Migraine
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more

Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions: Nivolumab, Azacitidine, Post Treatment Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Up to 39 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more

Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions: Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 482
States / cities: Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Intensive Care Unit Survivors, Informal Caregivers (Family and Friends)
Interventions: coping skills training, education program; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Pittsburgh, Pennsylvania + 1 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Metastasis Spine, Metastasis to Bone
Interventions: OsteoCool™ RF Ablation; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Phoenix, Arizona • Fullerton, California • Tampa, Florida + 9 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Cyclophosphamide, Methotrexate, Capecitabine; Drug
Lead sponsor: Harold J. Burstein, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Exisulind; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 114
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 92 more

Conditions: Stress Urinary Incontinence, Urinary Incontinence
Interventions: Behavioral Therapy, Intravaginal Pessary, Pessary combined with behavioral therapy; Behavioral · Device
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • Maywood, Illinois + 5 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 29
States / cities: Los Angeles, California • Menlo Park, California • San Jose, California + 19 more

Conditions: Ulcerative Colitis
Interventions: Adacolumn Apheresis System; Device
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Burbank, California • San Francisco, California + 22 more

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Apremilast, Etanercept, Placebo tablet, Placebo injection; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 31
States / cities: Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 35
States / cities: Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
Interventions: Efgartigimod IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: New Haven, Connecticut • New Orleans, Louisiana • Baltimore, Maryland + 6 more

Conditions: Heparin Induced Thrombocytopenia
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: Not listed
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 21
States / cities: Iowa City, Iowa • New Orleans, Louisiana • Baltimore, Maryland + 12 more

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more

Conditions: Breast Cancer
Interventions: letrozole, MRI, conventional surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 32
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 22 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 229
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: cisplatin, tirapazamine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 273
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 195 more

Search by objective public record fields.

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

A Post Market Study to Confirm the Safety and Performance of the Signia™ Stapling System.

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

OsteoCool Tumor Ablation Post-Market Study

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

ATLAS: Ambulatory Treatments for Leakage Associated With Stress

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Study for the Treatment of Ulcerative Colitis With Adacolumn

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

TRANSFORM-HF Ancillary Mechanistic Study

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer